Millions of individuals with Hepatitis C Virus (HCV) remain untreated despite the availability of existing therapies, highlighting a persistent unmet medical need for effective antiviral treatments. Current treatment regimens may be limited by factors such as tolerability, duration, or pan-genotypic coverage.

Atea Pharmaceuticals is developing oral direct-acting antiviral therapies, specifically a combination of bemnifosbuvir and ruzasvir, for the treatment of HCV. Both bemnifosbuvir and ruzasvir have demonstrated potent pan-genotypic antiviral activity against HCV as single agents. The combination therapy is currently in Phase 2 clinical trials, with the goal of providing a safe, effective, and short-duration treatment option for HCV patients. Atea leverages its expertise in antiviral drug development to advance novel product candidates targeting single-stranded ribonucleic acid (ssRNA) viruses.

Oral direct-acting antiviral agents for convenient administration.

Bemnifosbuvir: a nucleotide polymerase inhibitor.

Ruzasvir: an NS5A inhibitor.

Pan-genotypic antiviral activity, targeting a broad range of HCV genotypes.

Short treatment duration regimen.

Phase 2 clinical trial data demonstrating high rates of sustained virologic response (SVR).

The primary target audience includes individuals infected with Hepatitis C Virus (HCV) and healthcare providers specializing in the treatment of viral diseases.

Atea Pharmaceuticals anticipates generating revenue through the commercialization of bemnifosbuvir and ruzasvir, contingent upon successful completion of clinical trials and regulatory approval. The global HCV market was approximately >$3 billion in net sales in 2023.